Anika Therapeutics, Inc. Aktie News

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in  Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in  Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

BEDFORD, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on September 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise...

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options

Anika Therapeutics is an HA-platform company with regenerative, OA pain, and non-orthopedic products. Their main line is called Integrity. But Hyalofast and Cingal can also eventually target the sizeable cartilage and OA markets. ANIK's Integrity outperformed since launch, and their regenerative solutions have grown YoY. That's why the company believes it can also tap into the tendon-augmentati...

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK). The investigation concerns whether Anika and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.